Esperion Therapeutics (ESPR) Tops Q3 EPS by 18c; Reports Cash and Cash Equivalents of $153.7M

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($2.62), $0.18 better than the analyst estimate of ($2.80). Revenue for the quarter came in at $14.4 million versus the consensus estimate of $12.85 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Worthington Enterprises raises dividend 5%, adds board member